Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones

Eloxx Pharmaceuticals, Inc.

Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.
Tiered royalties on any future global sales of ZKN-013.
ZKN-013 is a Phase I ready oral therapy for nonsense mutations causing rare dermatologic diseases.
Almirall obtains worldwide rights to develop and commercialize ZKN-013.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).

Action: entry
Agreement: license
Counterparty: Almirall, S.A.
Value: $3.0 million
Effective: 2024-03-11

Exact text from the filing

entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-034529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.